Clinical Trial Update: Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome [Phase 2]

View source ↗

Summary

Phase 2 study evaluating droxidopa for chronic fatigue syndrome with orthostatic symptoms was terminated; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatigue Syndrome
• Neurally Mediated Hypotension
• Neurogenic Orthostatic Hypotension
• Orthostatic Hypotension

Drugs mentioned

• Northera (droxidopa)

Snippet

Sponsor: Chelsea Therapeutics | Conditions: Chronic Fatigue Syndrome, Orthostatic Hypotension | Phase 2 | Status: TERMINATED | Results posted: 2014-06-09